Plain Prescription Prices Act
- Sponsor
- Rep. Williams, Nikema [D-GA-5]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jul 22, 2025
Bottom line
The Plain Prescription Prices Act aims to increase transparency in drug pricing by requiring list prices to be displayed in direct-to-consumer television advertisements for federally covered medications.
What it actually does
This bill mandates that direct-to-consumer television advertisements for prescription drugs and biological products, for which payment is available under Medicare or Medicaid, must include a truthful and not misleading textual statement of the drug's list price. The list price would be determined on the first day of the quarter the advertisement airs, for a typical 30-day regimen or course of treatment. The Secretary of Health and Human Services, through the Administrator of the Centers for Medicare & Medicaid Services (CMS), is tasked with promulgating regulations to implement this requirement.
Proponents argue
Proponents argue that requiring pharmaceutical companies to disclose list prices in advertisements will empower consumers with critical information, enabling them to make more informed decisions about their healthcare. They contend that this transparency will foster greater competition among drug manufacturers, potentially leading to lower drug prices and improved affordability for patients, especially those relying on Medicare and Medicaid.
Opponents contend
Opponents might argue that displaying list prices in advertisements could be misleading to consumers, as many patients do not pay the full list price due to insurance coverage, rebates, and discounts. They may also contend that such a requirement could stifle pharmaceutical innovation by increasing regulatory burdens and potentially reducing advertising effectiveness, thereby impacting patient awareness of new treatments.
The bill is very short and easy to read, allowing for a quick understanding of its core provisions.
Section 2(a)
Requirement for Direct-to-Consumer Advertisement Pricing Information
This provision mandates that within one year of the bill's enactment, the Secretary of Health and Human Services, through the Administrator of CMS, must issue regulations. These regulations will require all direct-to-consumer advertisements on television (including broadcast, cable, streaming, and satellite) for prescription drugs or biological products covered by Medicare or Medicaid to display a textual statement. This statement must be truthful, not misleading, and indicate the drug's list price for a typical 30-day regimen or course of treatment, based on the price on the first day of the quarter the ad airs.
Supporters argue
Supporters argue this provision directly addresses the lack of transparency in drug pricing, allowing consumers to see a baseline cost before consulting with their doctors or pharmacists. This information is crucial for informed decision-making and can help patients understand the potential financial implications of a prescribed drug, especially for those whose out-of-pocket costs are tied to list prices.
Critics contend
Critics may contend that displaying only the list price can be misleading, as many patients, particularly those with comprehensive insurance, do not pay the full list price. They might argue that this could cause unnecessary alarm or confusion, potentially deterring patients from seeking necessary treatments if they misinterpret the list price as their actual out-of-pocket cost.
Tradeoffs
The provision balances the desire for greater price transparency with the potential for consumer confusion regarding the difference between list prices and actual out-of-pocket costs. It also navigates the tension between regulatory burden on pharmaceutical companies and the public's right to know drug costs.
Section 2(b)
Administrator's Determinations for Regulation Implementation
This section grants the Administrator of CMS the authority to make several key determinations when developing the regulations. These include deciding whether the pricing disclosure requirements should extend to other forms of advertising beyond television, specifying the exact manner and format for the textual price statements, establishing appropriate enforcement mechanisms for non-compliance, and determining if any other price information should be included in the advertisements.
Grants the Administrator of CMS the authority to determine whether the pricing disclosure regulations should apply to 'additional forms of advertising' beyond television.
Section 2(b)(1)
Why it matters:This is standard legislative practice to delegate specific implementation details to the relevant agency, allowing for flexibility and expert input without bogging down the primary legislation with granular specifics.
Case for: Allows the regulations to adapt to new advertising platforms (e.g., social media, digital ads) as they emerge, ensuring the spirit of the law remains relevant without requiring new legislation. This prevents the law from becoming quickly outdated.
Case against: Critics might argue that this grants too much power to the Administrator, potentially expanding the scope of the mandate beyond what Congress explicitly intended without further legislative review. It could lead to an unpredictable regulatory environment for advertisers.
Estimated impact: Potentially significant, as it could vastly expand the reach of the pricing disclosure requirement beyond traditional television, impacting a wider array of marketing channels and increasing compliance costs for pharmaceutical companies.